ArticleJournal of gastrointestinal oncology2026
Transcatheter arterial embolization with N-butyl cyanoacrylate versus gelatin sponge particles for gastric cancer-related upper gastrointestinal bleeding: a comparison of efficacy and safety.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute upper gastrointestinal bleeding (UGIB) is a common and life-threatening complication of advanced gastric cancer. Transcatheter arterial embolization (TAE) is a key treatment, but the optimal embolic agent remains uncertain. This single-center retrospective study aimed to compare the efficacy and safety of N-butyl cyanoacrylate (NBCA) versus gelatin sponge particles (GSPs) as embolic agents in TAE for gastric cancer-related UGIB (GC-UGIB). Methods: From January 2018 to December 2024, 85 patients undergoing TAE for GC-UGIB were analyzed. Patients were stratified by embolic agent: NBCA (n=36) and GSP (n=49). Primary outcomes included technical and clinical success, 30-day rebleeding rate, complications, and 30-day mortality. Multivariable logistic regression identified predictors of clinical success. Results: Technical success was 100% in both cohorts. The NBCA group was associated with a significantly higher rate of clinical success compared to the GSP group (86.1% Conclusions: In this retrospective study of TAE in GC-UGIB, NBCA is a safe and effective embolic agent, achieving superior clinical success and significantly lower medium- to long-term rebleeding rates compared to GSP. These findings suggest that NBCA may be a favorable embolic option, though prospective validation is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.